Keywords:
RANKL; acute lymphoblastic leukemia; bones; microenvironment; zoledronic acid
Abstract:
In summary, our findings shed light on the mechanisms of leukemia-induced bone loss and provide evidence for targeting the pathological interplay within the leukemia microenvironment as a novel therapeutic strategy for patients with pre-B ALL. Further studies evaluating the efficacy of zoledronic acid in combination with standard chemotherapy for pre-B ALL are now warranted.